Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue

Head and Neck

Volumn 32, Issue 11, 2010, Pages 1519-1527

  Pederson, Aaron W ^a   Haraf, Daniel J ^a   Witt, Mary Ellyn ^a   Stenson, Kerstin M ^a   Vokes, Everett E ^a   Blair, Elizabeth A ^a   Salama, Joseph K ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

base of tongue cancer; chemoradiotherapy; IMRT; induction chemotherapy; organ preservation

Indexed keywords

ALPHA2B INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; IRINOTECAN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCRIPTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA OF THE BASE OF TONGUE; TONGUE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; HYDROXYUREA; INTERFERON ALFA-2B; LEUCOVORIN; MALE; MIDDLE AGED; NECK DISSECTION; PACLITAXEL; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; TONGUE NEOPLASMS;

EID: 78649486415     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21360     Document Type: Article

References (50)

1. Han P, Hu K, Frank DK, Sessions RB, Harrison LB,. Management of cancer of the base of tongue. Otolaryngol Clin North Am 2005; 38: 75-85, viii.
2. Zhen W, Karnell LH, Hoffman HT, Funk GF, Buatti JM, Menck HR,. The National Cancer Data Base report on squamous cell carcinoma of the base of tongue. Head Neck 2004; 26: 660-674.
3. Jones AS, Rafferty M, Fenton JE, Jones TM, Husband DJ,. Treatment of squamous cell carcinoma of the tongue base: irradiation, surgery, or palliation? Ann Otol Rhinol Laryngol 2007; 116: 92-99.
4. Adelstein DJ,. Oropharyngeal cancer: the role of chemotherapy. Curr Treat Options Oncol 2003; 4: 3-13.
5. Bourhis J,. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 2004; 22 (; Suppl abstr 5505): 489s.
6. Chao KS, Ozyigit G, Blanco AI, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 2004; 59: 43-50.
7. de Arruda FF, Puri DR, Zhung J, et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006; 64: 363-373.
8. Argiris A, Haraf DJ, Kies MS, Vokes EE,. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist 2003; 8: 350-360.
9. Haraf DJ, Stenson K, List M, Witt ME, Weichselbaum RR, Vokes EE,. Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol 1997; 24 (1 Suppl 2): S2-68-S2-71.
10. Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008; 26: 1732-1741.
11. Salama JK, Haraf DJ, Stenson K, Milano MT, Witt ME, Vokes EE,. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J 2005; 11: 140-146.
12. Haraf DJ, Vokes EE, Weichselbaum RR, Panje WR,. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope 1992; 102: 630-636.
13. Vokes EE, Kies M, Haraf DJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol 1995; 13: 876-883.
14. Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 2003; 9 (16 Pt 1): 5936-5943.
15. Stenson KM, Haraf DJ, Pelzer H, et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg 2000; 126: 950-956.
16. List MA, Siston A, Haraf D, et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol 1999; 17: 1020-1028.
17. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
18. List MA, D'Antonio LL, Cella DF, et al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer 1996; 77: 2294-2301.
19. List MA, Ritter-Sterr C, Lansky SB,. A performance status scale for head and neck cancer patients. Cancer 1990; 66: 564-569.
20. Browman GP, Levine MN, Hodson DI, et al. The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. J Clin Oncol 1993; 11: 863-872.
21. Radloff L,. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
22. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Seiwert TY, Salama JK, Vokes EE,. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007; 4: 156-171.
24. Salama JK, Seiwert TY, Vokes EE,. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 2007; 25: 4118-4126.
25. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76.
26. Budach W, Hehr T, Budach V, Belka C, Dietz K,. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006; 6: 28.
27. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000; 83: 1594-1598.
28. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
29. Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004; 96: 1714-1717.
30. Pignon JP, Bourhis J, Domenge C, Designé L,. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-955.
31. Adelstein DJ, Saxton JP, Rybicki LA, et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006; 24: 1064-1071.
32. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 2002; 20: 3964-3971.
33. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003; 21: 320-326.
34. Brunin F, Mosseri V, Jaulerry C, Point D, Cosset JM, Rodriguez J,. Cancer of the base of the tongue: past and future. Head Neck 1999; 21: 751-759.
35. Housset M, Baillet F, Dessard-Diana B, Martin D, Miglianico L,. A retrospective study of three treatment techniques for T1-T2 base of tongue lesions: surgery plus postoperative radiation, external radiation plus interstitial implantation and external radiation alone. Int J Radiat Oncol Biol Phys 1987; 13: 511-516.
36. Jaulerry C, Rodriguez J, Brunin F, et al. Results of radiation therapy in carcinoma of the base of the tongue. The Curie Institute experience with about 166 cases. Cancer 1991; 67: 1532-1538.
37. Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Werning JW, Villaret DB,. Definitive radiotherapy for squamous cell carcinoma of the base of tongue. Am J Clin Oncol 2006; 29: 32-39.
38. Mendenhall WM, Stringer SP, Amdur RJ, Hinerman RW, Moore-Higgs GJ, Cassisi NJ,. Is radiation therapy a preferred alternative to surgery for squamous cell carcinoma of the base of tongue? J Clin Oncol 2000; 18: 35-42.
39. Barrett WL, Gleich L, Wilson K, Gluckman J,. Organ preservation with interstitial radiation for base of tongue cancer. Am J Clin Oncol 2002; 25: 485-488.
40. Gibbs IC, Le QT, Shah RD, Terris DJ, Fee WE, Goffinet DR,. Long-term outcomes after external beam irradiation and brachytherapy boost for base-of-tongue cancers. Int J Radiat Oncol Biol Phys 2003; 57: 489-494.
41. Harrison LB, Sessions RB, Strong EW, Fass DE, Nori D, Fuks Z,. Brachytherapy as part of the definitive management of squamous cancer of the base of tongue. Int J Radiat Oncol Biol Phys 1989; 17: 1309-1312.
42. Puthawala AA, Syed AM, Eads DL, Gillin L, Gates TC,. Limited external beam and interstitial 192iridium irradiation in the treatment of carcinoma of the base of the tongue: a ten year experience. Int J Radiat Oncol Biol Phys 1988; 14: 839-848.
43. Lee N,. Counterpoint: brachytherapy versus intensity-modulated radiation therapy in the management of base of tongue cancers. Brachytherapy 2005; 4: 5-7; discussion 8-9.
44. Nisi KW, Foote RL, Bonner JA, McCaffrey TV,. Adjuvant radiotherapy for squamous cell carcinoma of the tongue base: improved local-regional disease control compared with surgery alone. Int J Radiat Oncol Biol Phys 1998; 41: 371-377.
45. Thawley SE, Simpson JR, Marks JE, Perez CA, Ogura JH,. Preoperative irradiation and surgery for carcinoma of the base of the tongue. Ann Otol Rhinol Laryngol 1983; 92 (5 Pt 1): 485-490.
46. Sessions DG, Lenox J, Spector GJ, Chao C, Chaudry OA,. Analysis of treatment results for base of tongue cancer. Laryngoscope 2003; 113: 1252-1261.
47. Fakhry C, Gillison ML,. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006; 24: 2606-2611.
48. Salama JK, Stenson KM, Kistner EO, et al. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 2008; 19: 1787-1794.
49. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007; 25: 4873-4879.
50. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006; 66: 981-991.